Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.

Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A

The Journal of clinical endocrinology and metabolism1 Oct 2000Cited by 53 (Europe PMC)

PMID11061530DOI10.1210/jcem.85.10.6881PepBankPUB-11061530

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, daily GH normalized IGF-I in 15 of 18 patients (83.3%) versus 7 of 16 (43.7%) with thrice-weekly GH (P = 0.04).
In plain wordsIn GH-deficient adults, daily GH normalized IGF-I more often than thrice-weekly GH at three months.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I normalization at three months
Study
n = 34
Comparator
Thrice weekly GH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 3 monthsAs given in this study (human).
Measurements
Patients with normalized IGF-I at 3 months
83.3%
group A, daily rGH, 15 of 18
Patients with normalized IGF-I at 3 months
43.7%
group B, thrice weekly rGH, 7 of 16; P = 0.04
Source sentences
Summary
After 3 months of rGH treatment, IGF-I levels were normalized in 15 of 18 patients (83.3%) in group A and in 7 of 16 patients (43.7%) in group B (chi2 = 4.21; P = 0.04).
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153001
02HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, IGF-I was 202+/-57.5 microg/L with daily GH versus 155+/-45.1 microg/L with thrice-weekly GH (P = 0.001).
In plain wordsIn GH-deficient adults, daily GH produced higher IGF-I than thrice-weekly GH at three months.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I at three months
Study
n = 34
Comparator
Thrice weekly GH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 3 monthsAs given in this study (human).
Measurements
Serum IGF-I at 3 months
202 microg/L
group A, daily rGH; +/-57.5
Serum IGF-I at 3 months
155 microg/L
group B, thrice weekly rGH; +/-45.1; P = 0.001
Source sentences
Summary
At this time point, serum IGF-I levels in patients in group A (202+/-57.5 microg/L) were significantly higher than those in patients in group B (155+/-45.1 microg/L; P = 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153002
03HumanRandomized controlled trialEfficacy outcome
In GH-deficient adults, IGF-I was similar with daily and thrice-weekly GH at 6 months (223+/-35.2 versus 212+/-41.4 microg/L).
In plain wordsIn GH-deficient adults, IGF-I was similar with daily and thrice-weekly GH at six months.
Peptide
HGH (somatotropin)
Outcome
No significant changeIGF-I between schedules at six months
Study
n = 34
Comparator
Thrice weekly GH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 6 monthsAs given in this study (human).
Measurements
Serum IGF-I at 6 months
223 microg/L
group A, daily rGH; +/-35.2
Serum IGF-I at 6 months
212 microg/L
group B, thrice weekly rGH; +/-41.4
Source sentences
Summary
After 6 months of therapy, serum IGF-I levels were normalized in all patients and were similar in both groups (223+/-35.2 vs. 212+/-41.4 microg/L, A vs. B, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153004
04HumanRandomized controlled trialOther
In GH-deficient adults, all 16 thrice-weekly GH patients had good compliance, while 5 daily GH patients had poor compliance (P = 0.07).
In plain wordsIn GH-deficient adults, all thrice-weekly GH patients had good compliance, while five daily GH patients had poor compliance.
Peptide
HGH (somatotropin)
Outcome
Not applicableTreatment compliance
Study
n = 34
Comparator
Daily GH
Outcome group
Treatment adherence and retention · Endocrine and hormones
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Measurements
Patients with poor compliance
5 patients
group A, daily rGH; none reported in group B, thrice weekly; P = 0.07
Source sentences
Summary
All patients in group B had good compliance to the TIW treatment, whereas 5 patients in group A had poor compliance to the treatment (chi2 = 3.2; P = 0.07).
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153015
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, IGF-I normalized in all patients after 6 months of daily or thrice-weekly GH and remained normal through 12 months.
In plain wordsIn GH-deficient adults, both GH schedules normalized IGF-I by six months and maintained normal levels through twelve months.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I normalization at six months
Study
n = 34
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Measurements
Serum IGF-I at 6 months
223 microg/L
group A, daily rGH; +/-35.2
Serum IGF-I at 6 months
212 microg/L
group B, thrice weekly rGH; +/-41.4
Source sentences
Summary
After 6 months of therapy, serum IGF-I levels were normalized in all patients and were similar in both groups (223+/-35.2 vs. 212+/-41.4 microg/L, A vs. B, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
IGF-I levels remained normal until the 12-month follow-up.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153003
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, total cholesterol decreased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules reduced total cholesterol similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal cholesterol
Study
n = 34
Outcome group
Lipids · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153005
07HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, LDL cholesterol decreased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules reduced LDL cholesterol similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
DecreaseLDL cholesterol
Study
n = 34
Outcome group
Lipids · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153006
08HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, triglycerides decreased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules reduced triglycerides similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
DecreaseTriglycerides
Study
n = 34
Outcome group
Lipids · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153007
09HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, bioelectrical impedance decreased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules reduced bioelectrical impedance similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
DecreaseBioelectrical impedance
Study
n = 34
Outcome group
Body composition · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153008
10HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, body fat mass decreased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules reduced body fat mass similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
DecreaseBody fat mass
Study
n = 34
Outcome group
Body composition · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153009
11HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, HDL cholesterol increased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules increased HDL cholesterol similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
IncreaseHDL cholesterol
Study
n = 34
Outcome group
Lipids · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153010
12HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, lean body mass increased significantly after 6 months with both GH schedules, without between-schedule differences or further change at 12 months.
In plain wordsIn GH-deficient adults, both GH schedules increased lean body mass similarly, with no further change at twelve months.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass
Study
n = 34
Outcome group
Body composition · Metabolic and weight
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of rGH replacement, total cholesterol, low density lipoprotein cholesterol, triglycerides, bioelectrical impedance, and body fat mass were significantly reduced, whereas high density lipoprotein cholesterol levels and lean body mass were significantly increased in both groups of patie…
4 context sentences(design, population, supporting numbers)
Summary · context
No further change in lipid profile and body composition was observed after 12 months of treatment.
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153011
13HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, bone GLA protein increased significantly after 6 months of GH and showed a downward trend after 12 months.
In plain wordsIn GH-deficient adults, GH increased bone GLA protein at six months, with a downward trend at twelve months.
Peptide
HGH (somatotropin)
Outcome
MixedBone GLA protein
Study
n = 34
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
Serum bone GLA protein and procollagen III levels were significantly increased after 6 months, and a downward trend was observed after 12 months of rGH replacement.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153012
14HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, procollagen III increased significantly after 6 months of GH and showed a downward trend after 12 months.
In plain wordsIn GH-deficient adults, GH increased procollagen III at six months, with a downward trend at twelve months.
Peptide
HGH (somatotropin)
Outcome
MixedProcollagen III
Study
n = 34
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
Serum bone GLA protein and procollagen III levels were significantly increased after 6 months, and a downward trend was observed after 12 months of rGH replacement.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153013
15HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, bone mineral density increased slightly but significantly with both GH schedules only after 12 months (P = 0.0001).
In plain wordsIn GH-deficient adults, both GH schedules increased bone mineral density only after twelve months.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone mineral density
Study
n = 34
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Starting dose 10 microg/kg x day, subsequently adjusted · 12 monthsAs given in this study (human).
Source sentences
Summary
However, a slight, but significant, increase in bone mineral density was observed in both groups only after 12 months (P = 0.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Group A included 18 patients receiving daily rGH injections, and group B included 16 patients receiving TIW injections of rGH.
Summary · context
The starting dose of rGH was 10 microg/kg x day in both groups.
Summary · context
Subsequently, the dose was adjusted to maintain serum insulin-like growth factor I (IGF-I) concentrations in the normal age-adjusted range.
Report a problemFND-1106153014

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.